title: Changes in intraocular pressure after descemet stripping automated endothelial keratoplasty: a retrospective analysis.
abstract: OBJECTIVE
  To analyze the occurrence of postoperative intraocular pressure (IOP) elevation and types of pressure-lowering treatment in patients after Descemet stripping automated endothelial keratoplasty (DSAEK) with and without previous diagnoses of glaucoma and/or pseudoexfoliation (PXF) syndrome.
  
  
  METHODS
  This retrospective assessment considered 211 consecutive DSAEK cases (176 patients) performed by 1 surgeon between January 2007 and November 2010 with at least 1-year follow-up. Salient patient characteristics, IOP, and type of antiglaucoma treatment registered in postoperative visits up to 36 months were extracted from medical records. IOP elevation and its association with glaucoma, PXF, and combination of the 2 were assessed using multivariate ordinal logit models.
  
  
  RESULTS
  Of 211 eyes, 97 eyes (45%) showed at least 1 increase in IOP >25 mm Hg after DSAEK. Of these 97 eyes, 17 eyes (17.5%) had a history of glaucoma alone, another 17 eyes (17.5%) had a history of glaucoma combined with PXF, 10 eyes (9.7%) had PXF alone, and 53 eyes (54.6%) were steroid responders only. To control IOP elevation, steroid reduction alone was performed in 6 eyes (6.2%) and IOP-lowering medication as the only measure was performed in 26 eyes (26.8%). In 46 eyes (47.4%), steroids were reduced in combination with IOP-lowering medication and 16 eyes (16.5%) required surgery. In 3 eyes (3.1%), no action was required. Presence of PXF (odds ratio, 1.71; 95% confidence interval, 0.62-2.81; P = 0.002) and PXF glaucoma (1.14; 95% confidence interval, 0.06-2.21; P = 0.038) required a more intensive IOP-lowering management than patients without PXF with IOP problems.
  
  
  CONCLUSIONS
  Increased IOP is common after DSAEK, and a significant number of patients need IOP-lowering treatment. PXF syndrome and PXF glaucoma are risk factors for significant IOP elevation after DSAEK. In most cases, IOP remains controlled with conservative management, but some patients require glaucoma surgery.
authors.affiliation: *Department of Ophthalmology, Cantonal Hospital of Lucerne, Lucerne, Switzerland; and †Medignition Inc, Research Consultants, Zurich, Switzerland.
authors.forename: Luzia
authors.initials: L
authors.lastname: Müller
authors.forename: Claude
authors.initials: C
authors.lastname: Kaufmann
authors.forename: Lucas M
authors.initials: LM
authors.lastname: Bachmann
authors.forename: Janine N
authors.initials: JN
authors.lastname: Tarantino-Scherrer
authors.forename: Michael A
authors.initials: MA
authors.lastname: Thiel
authors.forename: Frank
authors.initials: F
authors.lastname: Bochmann
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D003316:Corneal Diseases / Q000503:physiopathology / Q000601:surgery*; D003886:Descemet Membrane / Q000601:surgery*; D057111:Descemet Stripping Endothelial Keratoplasty / Q000009:adverse effects*; D004728:Endothelium, Corneal / Q000637:transplantation*; D005260:Female; D005901:Glaucoma / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D011183:Postoperative Complications; D012189:Retrospective Studies; D012307:Risk Factors; D014065:Tonometry, Ocular
chemical_list: D000959:Antihypertensive Agents